Abstract
Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma. We analyzed pooled individual patient data for 1546 patients from 19 prospective clinical trials to assess treatment-specific factors (type of chemotherapy, rituximab, and concurrent combination antiretroviral [cART] use) and their influence on the outcomes complete response (CR), progression free survival (PFS), and overall survival (OS). In our analysis, rituximab was associated with a higher CR rate (odds ratio [OR] 2.89; P
Original language | English |
---|---|
Pages (from-to) | 3251-3262 |
Number of pages | 12 |
Journal | Blood |
Volume | 122 |
Issue number | 19 |
DOIs | |
Publication status | Published - Nov 7 2013 |
ASJC Scopus subject areas
- Hematology
- Biochemistry
- Cell Biology
- Immunology